While Ozempic maker Novo Nordisk has fallen on tough times, Wall Street analysts have still been reluctant to advise investors to sell the stock, until Deutsche Bank lowered the boom on Thursday.
Related stories
Second straight rate hike for Asia’s number-three economy as Nvidia-led AI expansion continues
My mother, 91, has dementia. Every bank says I need her signature to unlock her $100,000 stock certificate. What can I do?
Scott Bessent takes on the bond market
'End of an era' for ice cream shop open 106 years
China should be loosening budgetary policy. It’s doing the opposite
How India’s central bank subsidised the diaspora